Ridgeline Discovery
Gerald Gavory has a diverse work experience in the field of biology and drug discovery. Starting in 2003, they worked as a Postdoctoral Research Fellow at the University of Cambridge, focusing on the structure and function of human Telomerase. After that, they joined Merck as a Senior Research Biologist from 2005 to 2010. Gavory then held various positions at Almac Group, including Vice President Biology and Director of Biology. In 2018, they joined Ridgeline Discovery as the Director of Biology before transitioning to become the Senior Director of Drug Discovery and Translational Research at Monte Rosa Therapeutics in 2020. Currently, Gavory holds the position of VP Biology and EIR at Ridgeline Discovery, starting in 2023.
Gerald Gavory completed their Doctor of Philosophy (PhD) in Biological Sciences from the University of Cambridge from 1999 to 2003. Gerald then pursued a Postdoc degree at the same University from 2003 to 2005.
This person is not in any offices
Ridgeline Discovery
Ridgeline Discovery, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry and leading academics across Europe. In recent years, Ridgeline has assembled an international team of >50 highly experienced drug discovery professionals and built and operated several new successful companies, including Black Diamond Therapeutics (NASDAQ: BDTX), Bright Peak Therapeutics and Monte Rosa Therapeutics (NASDAQ: GLUE). Ridgeline is currently expanding its capabilities in Basel to support further company creation efforts in small molecules, biologics, and gene/cell therapy with focus on oncology and immunology.